Fact CheckerSign in

NCT07181213Enrolling by invitation

Genetic Predisposition to High Blood Pressure

Source: ClinicalTrials.gov · Last updated 2 Feb 2026

Brief summary (registry, in English)

Primary aldosteronism (PA) is a known but underdiagnosed cause of high blood pressure. It is estimated that more than 10% of all people with high blood pressure (HT) suffer from PA, which is often caused by aldosterone-producing adrenal cortical tumors (APAs). In a pilot study with 35 patients with APAs leading to hypertension, the investigators have identified a genetic variant in a presumed Calcium-channel gene. The variant was significantly overrepresented in patients with APAs compared to the normal population (12% compared to approximately 4%). Interestingly, all patients having APAs and the variant were men. The SCAPIS study is a world-unique Swedish research study in the field of heart/lungs, in which 30,000 randomly selected people between the ages of 50-64 participated. The study is a collaboration between the universities of Gothenburg, Lund, Linköping, Uppsala and Umeå, as well as the Karolinska Institute in Stockholm. In Linköping, about 5,000 persons participated. The investigators have now screened 4762 persons from the SCAPIS study for this variant and found it in little less than 6%. Overall, patients with the variant had more often been diagnosed with HT and were mote often treated for HT as well. Interestingly, this difference was only found in men. The investigators now want to investigate the following: 1. identify those persons with the genetic variant and HT that have PA, 2. identify those persons with PA that have APAs/unilateral disease, 3. identify how many patients with APAs/unilateral disease can be cured by surgery.

Status (registry)
Enrolling by invitation
Study type
Interventional
Enrollment
76 (estimated)
First submitted
12 Sept 2025
Start date
1 Jan 2026
Primary completion date
30 Jun 2027
Lead sponsor
Linkoeping University
NCT number
NCT07181213

What you commit to

  • Study type: Interventional
  • Planned participants: 76
  • From 1 Jan 2026 to the primary completion date, 30 Jun 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • patients who do not want to participate
  • patients who cannot give consent
  • patients who are too sick to be operated

Who the study is looking for

  • patients that participated in the SCAPIS study
  • patients that have a particular genetic variant
  • patients that have hypertension

Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Linkoping University Hospital
Coordinator of this site? Confirm its status
LinköpingSwedenUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.